Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EBITDA (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of EBITDA data on record, last reported at -$35.6 million in Q3 2025.

  • For Q3 2025, EBITDA fell 434.43% year-over-year to -$35.6 million; the TTM value through Sep 2025 reached -$109.0 million, up 22.15%, while the annual FY2024 figure was -$104.0 million, 62.06% up from the prior year.
  • EBITDA reached -$35.6 million in Q3 2025 per SGMO's latest filing, down from -$17.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $18.0 million in Q1 2023 and bottomed at -$123.6 million in Q2 2023.
  • Average EBITDA over 5 years is -$44.5 million, with a median of -$45.7 million recorded in 2022.
  • Peak YoY movement for EBITDA: crashed 1208.73% in 2021, then soared 139.84% in 2023.
  • A 5-year view of EBITDA shows it stood at -$39.9 million in 2021, then crashed by 38.83% to -$55.4 million in 2022, then fell by 12.04% to -$62.1 million in 2023, then soared by 58.12% to -$26.0 million in 2024, then plummeted by 36.79% to -$35.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$35.6 million in Q3 2025, -$17.9 million in Q2 2025, and -$29.6 million in Q1 2025.